S. 5237 — Introduced in Senate

II 119th CONGRESS 2d Session S. 5237 IN THE SENATE OF THE UNITED STATES August 4, 2026Ms. Hassan (for herself and Mr. Marshall) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions A BILL To require the Director of the National Institute of Allergy and Infectious Diseases to award a competitive grant for the Antibiotic Resistance Leadership Group for the purpose of facilitating a clinical research network on antibiotic resistance, and for other purposes. 1. Short title This Act may be cited as the Stop Superbugs Act. 2. Funding for antibiotic resistance clinical research (a) In general The Director of the National Institute of Allergy and Infectious Diseases shall award a competitive grant for the Antibiotic Resistance Leadership Group for the purpose of facilitating a clinical research network on antibiotic resistance, which shall include focuses on— (1) supporting rapid recruitment of clinical trial participants; (2) conducting clinical trial recruitment outreach in community settings; (3) supporting the pairing of diagnostic and pharmaceutical innovations during clinical trials; and (4) developing patient-reported outcomes in clinical studies. (b) Authorization of appropriations There is authorized to be appropriated to the Director of the National Institute of Allergy and Infectious Diseases such sums as may be necessary to carry out subsection (a).